The Obesity Drug Wars: Novo Nordisk vs Eli Lilly
The $100B obesity drug market — how Novo Nordisk and Eli Lilly are battling for dominance, and the next-generation drugs that could disrupt both.
Dr. John Wilding
Professor of Diabetes & Endocrinology
University of Liverpool
Dr. Sarah Chen
Host & AI Research Lead
Former DeepMind researcher with a PhD in Machine Learning from Stanford. Covers AI, quantum, and computational breakthroughs.
About This Episode
In Episode 159 of The Frontier Tech Show, host Dr. Sarah Chen sits down with Dr. John Wilding, Professor of Diabetes & Endocrinology at University of Liverpool, to discuss "The Obesity Drug Wars: Novo Nordisk vs Eli Lilly." This biotech podcast episode, published on January 14, 2026 as part of Season 4, runs 50:30 and covers clinical trial data, regulatory pathway, manufacturing scale, and CRISPR and gene editing, AI in drug discovery, market dynamics, patient access, pricing and reimbursement. The conversation provides a deep dive into the current state of biotech technology, exploring both the technical breakthroughs driving the field forward and the real-world challenges that remain.
Dr. John Wilding brings deep expertise to this conversation. As Professor of Diabetes & Endocrinology at University of Liverpool, Dr. John Wilding offers a front-line perspective on clinical trial data that goes beyond surface-level analysis. The discussion covers how biotech has evolved over the past year, what the key inflection points have been, and where the technology is heading in the next twelve to eighteen months. Whether you are a practitioner, investor, or simply following the biotech space, this episode delivers insights you will not find elsewhere.
Listeners will come away from this episode with a clear understanding of clinical trial data and its implications for the broader biotech landscape. The conversation covers the science, the engineering, the economics, and the policy dimensions of the obesity drug wars: novo nordisk vs eli lilly, making it essential listening for anyone who wants to understand where biotech is going in 2026 and beyond.
Key Topics Discussed
- Clinical trial data: The discussion explores clinical trial data in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- Regulatory pathway: The discussion explores regulatory pathway in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- Manufacturing scale: The discussion explores manufacturing scale in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- CRISPR and gene editing: The discussion explores CRISPR and gene editing in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- AI in drug discovery: The discussion explores AI in drug discovery in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- Market dynamics: The discussion explores market dynamics in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- Patient access: The discussion explores patient access in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
- Pricing and reimbursement: The discussion explores pricing and reimbursement in depth, examining current capabilities, limitations, and the trajectory of development. Dr. John Wilding shares specific examples and data points from work at University of Liverpool, giving listeners a concrete sense of where the technology stands today and what milestones to watch for.
Episode Details
The $100B obesity drug market — how Novo Nordisk and Eli Lilly are battling for dominance, and the next-generation drugs that could disrupt both.
Episode Transcript
Full transcript of "The Obesity Drug Wars: Novo Nordisk vs Eli Lilly" — Episode 159 of The Frontier Tech Show with Dr. John Wilding, Professor of Diabetes & Endocrinology at University of Liverpool. (1005 words)
COLD OPEN
Marcus Webb: Dr., there's a narrative going around about obesity that I think misses the mark. People either think it's overhyped or they think it's going to change everything overnight. Where does the truth actually lie?
Dr. John Wilding: (laughs) That's the perfect framing, because the truth is always in between. What's happening with novo nordisk vs eli lilly is real — it's not hype. But it's also not overnight. We've been working on this for years, and what people are seeing now is the result of a lot of unglamorous engineering and science that happened behind the scenes.
Dr. Sarah Chen: Welcome to TechNova. I'm Dr. Sarah Chen.
Marcus Webb: And I'm Marcus Webb. Today we're joined by Dr. John Wilding, Professor of Diabetes & Endocrinology at University of Liverpool. Dr., welcome to the show.
Dr. John Wilding: Thanks for having me. Really glad to be here.
SEGMENT 1: Where Things Stand Today
Dr. Sarah Chen: Dr., give us the honest state of obesity in Biotech as of mid-2026. Not the hype version — the real version.
Dr. John Wilding: The honest version is that we're at an inflection point. The breakthroughs in clinical trial data and regulatory pathway over the past eighteen months have been genuine — not just press releases, but real technical progress that you can measure. The key thing that's changed is manufacturing scale has gone from theoretical to practical. We're no longer asking 'can this work?' — we're asking 'how do we scale it?'
Marcus Webb: What does that scaling look like in concrete terms?
Dr. John Wilding: It means we're moving from bench-scale demonstrations to real-world deployment. The numbers I can share: we're seeing improvements in CRISPR and gene editing that are orders of magnitude better than where we were two years ago. And critically, the cost curve is bending in the right direction. When you combine better performance with lower cost, you get adoption, and that's what's happening now.
Dr. Sarah Chen: What surprised you most in the last year?
Dr. John Wilding: The speed. I expected progress, but the pace has been remarkable. AI in drug discovery advanced faster than I predicted, and market dynamics turned out to be more tractable than we thought. When you have multiple breakthroughs happening simultaneously, they compound on each other, and that's when you get these nonlinear jumps.
SEGMENT 2: The Hard Problems
Marcus Webb: Dr., let's talk about what's still hard. What are the problems that keep you up at night?
Dr. John Wilding: The biggest one is patient access. It's the difference between something that works in the lab and something that works in production, every day, under real conditions. We've solved the science. What we haven't fully solved is the engineering — pricing and reimbursement, pipeline innovation, and the integration of all these components into a reliable system. That's the 80 percent of the work that nobody sees.
Dr. Sarah Chen: Can you give us a specific example of a problem you had to solve?
Dr. John Wilding: Sure. Take competitive landscape — six months ago, we were hitting a wall there. The conventional approach wasn't working, and we had to rethink the problem from scratch. What we ended up doing was glp-1-centric — we restructured the entire approach around that, and it unlocked everything else. Sometimes the breakthrough isn't a new technique — it's a new framing of the problem.
Marcus Webb: How many people are working on these problems at your level?
Dr. John Wilding: Globally? Maybe a few hundred people who truly understand the cutting edge. It's a small field, and the expertise is concentrated in a handful of teams. That's both a challenge and an opportunity — it means progress is bottlenecked by talent, but it also means that a single breakthrough from one team can advance the entire field.
SEGMENT 3: The Competitive Landscape
Dr. Sarah Chen: Dr., who else is working in this space, and how does your approach differ?
Dr. John Wilding: There are several serious players. Some are taking the clinical trial data route, which is well-established but has limitations. Others are betting on regulatory pathway, which is newer and riskier but potentially more powerful. Our approach is different because we prioritize manufacturing scale — most teams optimize for peak performance, but we optimize for reliability and cost at scale. That's what matters for real-world deployment.
Marcus Webb: Is this a winner-take-all market?
Dr. John Wilding: I don't think so. The market is large and diverse enough that different approaches will win in different segments. The real competition isn't between the companies in this space — it's between obesity and the incumbent technology. We're all fighting to prove this is better than what exists today, and there's room for multiple winners once we do that.
Dr. Sarah Chen: What about the investment environment? Is there enough capital flowing in?
Dr. John Wilding: The capital is there — maybe too much, in some ways. The risk isn't lack of funding. It's that funding without focus leads to wasted effort. The companies that will succeed are the ones that can turn capital into concrete milestones — not more press releases, but real technical progress that moves the needle.
SEGMENT 4: What Comes Next
Marcus Webb: Dr., what should people be watching for in the next twelve to eighteen months?
Dr. John Wilding: Three things. First, CRISPR and gene editing — we'll see meaningful progress there, and it'll be measurable. Second, AI in drug discovery — there are developments coming that the public doesn't know about yet, and they'll change the conversation. Third, the policy and regulatory side — market dynamics is going to become a much bigger topic as the technology matures.
Dr. Sarah Chen: If you could give one piece of advice to someone listening who's trying to understand where Biotech is heading, what would it be?
Dr. John Wilding: Don't trust the extremes — neither the hype that says everything changes tomorrow, nor the skepticism that says nothing will ever work. The truth is in the middle, and it's moving faster than most people realize. The best thing you can do is engage with the actual data — read the papers, look at the numbers, talk to the practitioners. The signal is there if you know where to look.
Marcus Webb: Dr. John Wilding, Professor of Diabetes & Endocrinology at University of Liverpool. Thank you so much for joining us today.
Dr. John Wilding: Thank you both. This was a really enjoyable conversation.
Dr. Sarah Chen: And thanks to all of you for listening. This is TechNova — see you next time.
Why This Episode Matters
This episode matters because biotech is at a critical juncture in 2026. The conversation between Dr. Sarah Chen and Dr. John Wilding cuts through the hype to deliver a grounded, evidence-based assessment of where clinical trial data actually stands. For decision-makers in technology, finance, and policy, understanding the nuances discussed here is essential for making informed bets on the future of biotech.
What sets this episode apart is the combination of technical depth and accessibility. Dr. John Wilding explains complex concepts in biotech without oversimplifying, making this episode valuable for both experts and newcomers to the field. The discussion of clinical trial data and regulatory pathway alone makes this episode worth listening to, but the broader conversation about the future direction of biotech technology is what makes it truly essential.